Tekcapital portfolio company Belluscura (LON:BELL) have provided an update on the roll-out of their portable oxygen devices, alongside the announcement of a distribution agreement with a leading US supplier. Tekcapital has a 14% stake in AIM-listed Belluscura, currently valued in the region of £11m.
Download your research report now for instant access.
Please read the High Net Worth Individual Statement or Sophisticated Investor Statement before downloading this guide.
Kemeny Capital is exclusively aimed at UK resident persons who are required to self-certify as either a Sophisticated Investor or High Net Worth Individual.
The value of investments may go up as well as down and there is no guarantee of any investment return. Investments in private companies carry significant risks including loss of capital, illiquidity, and no guarantee of regular income from the investment. You should understand the risks involved and be capable of making investment decisions based upon your personal circumstances. Past Performance is not an indicator of future performance.
Kemeny Capital does not provide advice on Investments, tax or legal affairs.
Kemeny Capital Ltd is Authorised and Regulated by the Financial Conduct Authority, FCA Register Number 941978
Kemeny Capital, 71-75 Shelton Street, London, Registered in England, Company Number 12871856